Product Description and Packaging Sample Clauses

Product Description and Packaging. ABI shall package and supply the Product, i.e., the FSH Midstream Test Stick, to SYNOVA as follows: the Product will be packaged in a 4-color, OTC quality box, enclosed in clear outer wrap. Each box shall contain two (2) FSH Midstream Test Stick, each consisting of a Top, Bottom, Cap and Test Strip. Each Test Stick shall be wrapped in a generic white foil pouch, stamped with the Product Name, Expiration Date, Lot Number and Catalog Number. A Desiccant Pouch shall be inserted in each foil pouch to prevent moisture. The wrapped Test Sticks shall be placed inside the OTC box, along with a 2-color package insert The boxed Test Sticks shall be placed in a 4-color Shelf Tray holding six (6) units, and packaged in a Shipper Box holding two Shelf Trays (12 units).
Sample 1
AutoNDA by SimpleDocs
Product Description and Packaging. ABI shall package and supply the Product, i.e., the FSH Midstream Test Stick, to SYNOVA as follows: the Product will be packaged in a 4-color, OTC quality box, enclosed in clear outer wrap. Each box shall contain two (2) FSH Midstream Test Stick, each consisting of a Top, Bottom, Cap and Test Strip. Each Test Stick shall be wrapped in a generic white foil pouch, stamped with the Product Name, Expiration Date, Lot Number and Catalog Number. A Desiccant Pouch shall be inserted in each foil pouch to prevent moisture. The wrapped Test Sticks shall be placed inside the OTC box, along with a 2-color package insert The boxed Test Sticks shall be placed in a 4-color Shelf Tray holding six (6) units, and packaged in a Shipper Box holding two Shelf Trays (12 units). SYNOVA agrees to specify and provide ABI with Art Work for the Bar Code, OTC Box, Test Stick printing (if any), Package Insert Cover, Shelf Tray and Shipper Box. Product packaging does not include any items not specified above, such as promotional coupons, labels or security sensors. Any such additional items would be specified by SYNOVA, and provided, by agreement between the parties, and may result in higher costs.
Sample 1
Product Description and Packaging. BioPad shall package and supply the Licensed Products in the manner agreed upon by the parties. To the extent that BioPad is to use particular art work in connection with the packaging of the Licensed Products, unless otherwise agreed upon by the parties Synova will specify and provide BioPad with such art work.
Sample 1

Related to Product Description and Packaging

  • Labeling and Packaging BTG shall label and package the Bulk Product in accordance with Legal Requirements applicable to pharmaceutical products shipped in bulk for further processing, labeling, or repackaging.

  • Product Description The Products are described in the Product Unique Attachment(s). Products also include all FRUs, CSPs, Product code, and Product documentation.

  • Packaging and Labeling 11.1 Company shall provide packaging and labeling specifications that call out clear labeling requirements.

  • Packaging All Material shall be packaged in accordance with ATA 300 Specification, Category III for consumable/expendable material and Category II for rotables. Category I containers shall be used if requested by the Buyer and the difference between Category I and Category II packaging costs shall be paid by the Buyer together with payment for the respective Material.

  • Manufacturing Intrexon shall have the option and, in the event it so elects, shall use Diligent Efforts, to perform any manufacturing activities in connection with the Aquaculture Program that relate to the Intrexon Materials, including through the use of a suitable Third Party contract manufacturer. To the extent that Intrexon so elects, Intrexon may request that AquaBounty and Intrexon establish and execute a separate manufacturing and supply agreement, which agreement will establish and govern the production, quality assurance, and regulatory activities associated with manufacture of Intrexon Materials. Except as provided in Section 4.1, any manufacturing undertaken by Intrexon pursuant to the preceding sentence shall be performed in exchange for cash payments equal to Intrexon’s Fully Loaded Cost in connection with such manufacturing, on terms to be negotiated by the Parties in good faith. In the event that Intrexon does not manufacture Intrexon Materials or bulk quantities of other components of AquaBounty Products, then Intrexon shall provide to AquaBounty or a contract manufacturer selected by AquaBounty and approved by Intrexon (such approval not to be unreasonably withheld) all Information Controlled by Intrexon that is (a) related to the manufacturing of such Intrexon Materials or bulk qualities of other components of AquaBounty Products for use in the Field and (b) reasonably necessary to enable AquaBounty or such contract manufacturer (as appropriate) for the sole purpose of manufacturing such Intrexon Materials or bulk quantities of other components of AquaBounty Products. The costs and expenses incurred by Intrexon in carrying out such transfer shall be borne by Intrexon. Any manufacturing Information transferred hereunder to AquaBounty or its contract manufacturer shall not be further transferred to any Third Party, including any Product Sublicensee, or any AquaBounty Affiliate without the prior written consent of Intrexon; provided, however, that Intrexon shall not unreasonably withhold such consent if necessary to permit AquaBounty to switch manufacturers.

  • Project Description The Project Description may be changed from time to time by, or with the consent of, the Company provided that any such change shall also be filed with the Issuer and provided further that no change in the Project Description shall materially change the function of the Project Facilities unless the Trustee shall have received (i) an Engineer's certificate that such changes will not impair the significance or character of the Project Facilities as Pollution Control Facilities and (ii) an Opinion of Bond Counsel or ruling of the Internal Revenue Service to the effect that such amendment will not adversely affect the exclusion of interest on the Bonds from gross income for federal income tax purposes.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Product Development SB shall have responsibility for, and control of, the development and commercialization of each Product arising from this Agreement, including process development, delivery system and formulation development, preclinical studies, clinical studies, sales and marketing.

  • Marketing Materials (a) During the term of this Agreement, the Sub-Adviser agrees to furnish the Manager at its principal office for prior review and approval by the Manager all written and/or printed materials, including but not limited to, PowerPointÒ or slide presentations, news releases, advertisements, brochures, fact sheets and other promotional, informational or marketing materials (the “Marketing Materials”) for internal use or public dissemination, that are produced or are for use or reference by the Sub-Adviser, its affiliates or other designees, broker-dealers or the public in connection with the Series, and Sub-Adviser shall not use any such materials if the Manager reasonably objects in writing within five business days (or such other period as may be mutually agreed) after receipt thereof. Marketing Materials may be furnished to the Manager by first class or overnight mail, facsimile transmission equipment, electronic delivery or hand delivery.

Time is Money Join Law Insider Premium to draft better contracts faster.